Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

British Journal of Cancer

Volumn 71, Issue 3, 1995, Pages 587-591

  Pyrhonen S ^a   Kuitunen, T ^a   Nyandoto, P ^a   Kouri, M ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chemotherapy; Gastric cancer; Survival

Indexed keywords

ALPHA TOCOPHEROL; ANTIEMETIC AGENT; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; RETINOL;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN DISEASE; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; STOMACH NEOPLASMS; VITAMIN A; VITAMIN E;

EID: 0028959887     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.114     Document Type: Article

References (20)

1. COCCONI G. (1994). Chemotherapy of advanced gastric carcinoma: to be completely rewritten? Ann. Oncol., 5(8), 8-11.
2. CULLINAN SA, MOERTEL CG, FLEMING TR, RUBIN JR, KROOK JE, EVERSON LK, WINDSCHITL HE, TWITO DI, MARSCHKE RF, FOLEY JF, PFEIFLE DM and BARLOW JF. (1985). A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin and mitomycin, JAMA, 253, 2061-2067.
3. DUPONT JB, LEE JR, BURTON GR and COHN I. (1978). Adenocarcinoma of the stomach: review of 1497 cases, Cancer, 41, 941-953.
4. ELLIS P and CUNNINGHAM D. (1994). Management of carcinomas of the upper gastrointestinal tract, Br, Med, J., 388, 834-838.
5. FINDLAY M and CUNNINGHAM D. (1993). Chemotherapy of carcinoma of the stomach, Cancer Treat, Rev., 19, 29-44.
6. HAYWARD JL and RUBENS RD. (1977). Assessment of response to therapy in advanced breast cancer, Br, J. Cancer, 35, 292-298.
7. KELSEN D, ATIQ OT, SALTZ L, NIEDZWIECKI D, GINN D, CHAPMAN D, HEELAN R LIGHTDALE C, VINCIGUERRA V and BRENNAN M. (1992). FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer, J. Clin Oncol., 10, 541-548.
8. KELSEN D, KARPEH M, SCHWARTZ G, SALTTZ L, ILSON D, HUANG Y and BRENNAN M. (1994). Neoadjuvant and postoperative chemotherapy for high-risk gastric cancer, Proc, Am, Soc, Clin, Oncol., 13, 195.
9. KLEIN HO, WICKRAMANAYAKE PD, DIETERLE F, MOHR R, OER-KERMANN H and GROSS R (1983). High-dose MTX 5-FU and adriamycin for gastric cancer, Semin, Oncol., 2 (Suppl. 2), 29-31.
10. KOHNOE S, YOSHIDA M, TAKAHASHI I, EMI Y, MAEHARA Y and SUGIMACHI K. (1992). Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells, Anticancer Res., 12, 389-392.
11. MILLER AB, HOOGSTRATEN B, STAQUET M and WINKLER A. (1981). Reporting results of cancer treatment, Cancer, 47, 207-214.
12. MOERTEL CG. (1968). The natural history of advanced gastric cancer, Surg, Gynecol, Obstet., 126, 1071-1074.
13. MURAD AM, SANTIAGO FF, PETROIANU A, ROCHA PRS, RODRIGUES MAG and RAUSCH M. (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer, Cancer, 72, 37-41.
14. PETO R PIKE MC and ARM IT AGE P. (1977). Design and analysis of randomised clinical trial requiring prolonged observation of each patient, Br, J. Cancer, 35, 1-39.
15. PYRHÖNEN SO and KOURI MO. (1992). Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer, Eur, J. Cancer, 28A, 1828-1832.
16. PYRHÖNEN S and VALTONEN M. (1990). Response to doxorubicin methotrexate fluorouracil in advanced adenocarcinoma of pancreas or biliary tract Lancet, 336, 127.
17. WILKE H, PREUSSER P, FINK U, ACTERRATH W, MEYER H-J, STAHL M, LENAZ L, MEYER J, SIEWERT JR, GEERLINGS H, KÖHNE-WÖMPNER CH, HARSTRIC A and SCHMOLL H-J (1990). New developments in the treatment of gastric cancer, Semin, Oncol., 17, 61-70.
18. WILS JA. (1992). Chemotherapy for gastrointestinal cancer, new hopes or new disappointments? Scand, J. Gastroenterol., 27 (Suppl. 194), 87-94.
19. WILS J, BUSS JM, COOMBES R AMADORI D, FOUNTZILAS G, KLEIN HO, PINTO-FERREIRA E, REIS H, VASSILOPOULOS P and WOODS E. (1990). Phase I-II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) combined with epirubicin (E) [FEMTX] in advanced gastric cancer (meeting abstract). Ann, Oncol., 1 (Suppl.), 43.
20. WILS JA, KLEIN HO, WAGENER DJTH, BLEIBERG H, REIS H, KORSTEN F, CONROY TH, FICKERS M, LEYVRAZ S, BUYSE M and DUEZ N. (1991). Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer, a trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group, J. Clin, Oncol., 9, 827-831.